Want to see TSE:DOSE full AI Analyst Report?

Rapid Dose Therapeutics Corp (DOSE) Ratios

8 Followers

Rapid Dose Therapeutics Corp Ratios

TSE:DOSE's free cash flow for Q4 2026 was C$-0.34. For the 2026 fiscal year, TSE:DOSE's free cash flow was decreased by C$ and operating cash flow was C$-0.66. See a summary of the company’s cash flow.

Ratios	TTM	May 26	May 25	May 24	Nov 22
Liquidity Ratios
Current Ratio	―	0.04	0.10	0.23	0.25
Quick Ratio	―	0.02	0.06	0.19	0.15
Cash Ratio	―	<0.01	<0.01	0.06	0.01
Solvency Ratio	―	-0.28	-0.75	-0.73	-2.74
Operating Cash Flow Ratio	―	-0.03	-0.17	-0.79	-1.22
Short-Term Operating Cash Flow Coverage	―	-0.09	-0.44	-7.66	-3.95
Net Current Asset Value	C$ ―	C$ -10.09M	C$ -6.18M	C$ -4.36M	C$ -2.20M
Leverage Ratios
Debt-to-Assets Ratio	―	1.62	1.60	1.30	0.47
Debt-to-Equity Ratio	―	-0.74	-0.50	-0.78	5.69
Debt-to-Capital Ratio	―	-2.87	-1.01	-3.48	0.85
Long-Term Debt-to-Capital Ratio	―	0.00	0.00	-2.06	0.00
Financial Leverage Ratio	―	-0.46	-0.31	-0.60	12.20
Debt Service Coverage Ratio	―	-0.39	-1.02	-3.15	-8.50
Interest Coverage Ratio	―	-1.78	4.39	-5.65	-33.23
Debt to Market Cap	―	0.15	0.12	0.13	0.03
Interest Debt Per Share	―	0.05	0.03	0.03	0.02
Net Debt to EBITDA	―	-3.20	-0.66	-0.76	-0.18
Profitability Margins
Gross Profit Margin	―	-34.50%	56.59%	55.24%	76.77%
EBIT Margin	―	-78.29%	-200.07%	-357.35%	-476.83%
EBITDA Margin	―	-59.78%	-188.53%	-296.57%	-433.11%
Operating Profit Margin	―	-78.29%	259.18%	-366.57%	-253.14%
Pretax Profit Margin	―	-122.22%	-259.18%	-422.16%	-484.42%
Net Profit Margin	―	-122.22%	-259.18%	-422.16%	-484.42%
Continuous Operations Profit Margin	―	-122.22%	-259.18%	-422.16%	-484.42%
Net Income Per EBT	―	100.00%	100.00%	100.00%	100.00%
EBT Per EBIT	―	156.12%	-100.00%	115.16%	191.36%
Return on Assets (ROA)	―	-103.26%	-330.55%	-228.42%	-276.61%
Return on Equity (ROE)	―	47.24%	103.82%	136.35%	-3373.73%
Return on Capital Employed (ROCE)	―	42.06%	-103.82%	361.93%	-720.26%
Return on Invested Capital (ROIC)	―	117.10%	-208.20%	530.90%	-263.34%
Return on Tangible Assets	―	-103.26%	-330.55%	-228.42%	-276.61%
Earnings Yield	―	-17.00%	-25.52%	-23.44%	-32.57%
Efficiency Ratios
Receivables Turnover	―	16.48	6.89	4.65	9.59
Payables Turnover	―	0.80	0.47	0.41	0.30
Inventory Turnover	―	23.29	3.66	3.45	1.72
Fixed Asset Turnover	―	0.97	2.15	0.85	0.71
Asset Turnover	―	0.84	1.28	0.54	0.57
Working Capital Turnover Ratio	―	-0.39	-0.50	-0.31	-0.61
Cash Conversion Cycle	―	-419.90	-628.95	-711.12	-969.75
Days of Sales Outstanding	―	22.15	52.97	78.48	38.08
Days of Inventory Outstanding	―	15.67	99.61	105.80	212.15
Days of Payables Outstanding	―	457.72	781.53	895.40	1.22K
Operating Cycle	―	37.82	152.58	184.28	250.23
Cash Flow Ratios
Operating Cash Flow Per Share	―	>-0.01	>-0.01	-0.02	-0.03
Free Cash Flow Per Share	―	>-0.01	>-0.01	-0.02	-0.03
CapEx Per Share	―	<0.01	<0.01	0.00	<0.01
Free Cash Flow to Operating Cash Flow	―	1.00	1.01	1.00	1.01
Dividend Paid and CapEx Coverage Ratio	―	-301.78	-199.79	0.00	-74.33
Capital Expenditure Coverage Ratio	―	-301.78	-199.79	0.00	-74.33
Operating Cash Flow Coverage Ratio	―	-0.05	-0.44	-0.94	-2.09
Operating Cash Flow to Sales Ratio	―	-0.10	-0.55	-2.25	-1.71
Free Cash Flow Yield	―	-1.36%	-5.44%	-12.49%	-11.67%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-5.88	-3.92	-4.27	-3.07
Price-to-Sales (P/S) Ratio	―	7.19	10.16	18.01	14.87
Price-to-Book (P/B) Ratio	―	-2.78	-4.07	-5.82	103.58
Price-to-Free Cash Flow (P/FCF) Ratio	―	-73.51	-18.37	-8.00	-8.57
Price-to-Operating Cash Flow Ratio	―	-73.75	-18.47	-8.00	-8.69
Price-to-Earnings Growth (PEG) Ratio	―	0.14	-0.67	-0.38	-0.01
Price-to-Fair Value	―	-2.78	-4.07	-5.82	103.58
Enterprise Value Multiple	―	-15.23	-6.05	-6.83	-3.62
Enterprise Value	―	25.25M	23.77M	20.66M	27.45M
EV to EBITDA	―	-15.23	-6.05	-6.83	-3.62
EV to Sales	―	9.11	11.40	20.26	15.67
EV to Free Cash Flow	―	-93.08	-20.62	-9.00	-9.03
EV to Operating Cash Flow	―	-93.39	-20.72	-9.00	-9.15
Tangible Book Value Per Share	―	-0.05	-0.04	-0.03	<0.01
Shareholders’ Equity Per Share	―	-0.05	-0.04	-0.03	<0.01
Tax and Other Ratios
Effective Tax Rate	―	0.00	0.00	0.00	0.00
Revenue Per Share	―	0.02	0.02	<0.01	0.02
Net Income Per Share	―	-0.03	-0.04	-0.04	-0.08
Tax Burden	―	1.00	1.00	1.00	1.00
Interest Burden	―	1.56	1.30	1.18	1.02
Research & Development to Revenue	―	0.01	0.07	0.42	0.21
SG&A to Revenue	―	0.43	2.38	2.31	2.41
Stock-Based Compensation to Revenue	―	0.00	0.68	0.16	0.97
Income Quality	―	0.08	0.21	0.53	0.35

Currency in CAD